ATE398633T1 - Neovaskulär gerichtete immunkonjugate - Google Patents

Neovaskulär gerichtete immunkonjugate

Info

Publication number
ATE398633T1
ATE398633T1 AT00941443T AT00941443T ATE398633T1 AT E398633 T1 ATE398633 T1 AT E398633T1 AT 00941443 T AT00941443 T AT 00941443T AT 00941443 T AT00941443 T AT 00941443T AT E398633 T1 ATE398633 T1 AT E398633T1
Authority
AT
Austria
Prior art keywords
immunoconjugates
alanine
neovascular
factor vii
effector domain
Prior art date
Application number
AT00941443T
Other languages
English (en)
Inventor
Alan Garen
Zhiwei Hu
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Application granted granted Critical
Publication of ATE398633T1 publication Critical patent/ATE398633T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00941443T 1999-07-01 2000-06-14 Neovaskulär gerichtete immunkonjugate ATE398633T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14216199P 1999-07-01 1999-07-01

Publications (1)

Publication Number Publication Date
ATE398633T1 true ATE398633T1 (de) 2008-07-15

Family

ID=22498780

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00941443T ATE398633T1 (de) 1999-07-01 2000-06-14 Neovaskulär gerichtete immunkonjugate

Country Status (11)

Country Link
EP (1) EP1198479B1 (de)
JP (2) JP2003504315A (de)
AT (1) ATE398633T1 (de)
AU (1) AU775621B2 (de)
CA (1) CA2377381C (de)
CY (1) CY1110394T1 (de)
DE (1) DE60039240D1 (de)
DK (1) DK1198479T3 (de)
ES (1) ES2307517T3 (de)
PT (1) PT1198479E (de)
WO (1) WO2001002439A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US6423826B1 (en) * 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US7323440B2 (en) 2002-02-13 2008-01-29 Micromet Ag De-immunized MOG (poly)peptide constructs
AU2003220091B2 (en) * 2002-03-08 2006-02-16 Emory University Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis
WO2003076461A2 (en) * 2002-03-12 2003-09-18 Novo Nordisk A/S Dimeric tf antagonist comprising two factor vii polypeptides
AU2003242507A1 (en) * 2002-07-12 2004-02-02 Novo Nordisk A/S A tissue factor binding immunoconjugate comprising factor viia
WO2004007557A2 (en) * 2002-07-12 2004-01-22 Novo Nordisk A/S Tf antagonist
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
EP2298347B1 (de) 2003-05-06 2015-09-30 Biogen Hemophilia Inc. Chimäre Proteine mit Gerinnungsfaktor zur Behandlung von hämostatischen Erkrankungen
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
AU2012203896B2 (en) * 2003-05-06 2014-09-25 Bioverativ Therapeutics Inc. Clotting Factor-Fc Chimeric Proteins to Treat Hemophilia
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
WO2005025623A2 (en) * 2003-07-28 2005-03-24 Emory University Ef-24-factor vii conjugates
EP1684790A4 (de) * 2003-11-18 2008-04-30 Iconic Therapeutics Inc Homogene präparate von chimeren proteinen
JP2009203161A (ja) * 2006-06-05 2009-09-10 Mebiopharm Co Ltd リウマチ治療薬
MX2013000301A (es) 2010-07-09 2013-05-09 Biogen Idec Hemophilia Inc Factores quimericos de coagulacion.
AU2017206445B2 (en) 2016-01-15 2019-07-18 Rigshospitalet Quantitative pet imaging of tissue factor expression using 18F-labled active site inhibited factor VII
WO2017181145A1 (en) * 2016-04-14 2017-10-19 Iconic Therapeutics, Inc. Compositions and methods for treating disorders associated with νeοvascularization
WO2018091058A1 (en) 2016-11-17 2018-05-24 Rigshospitalet 177-lu labeled active site inhibited factor vii
AU2018235945A1 (en) * 2017-03-14 2019-10-17 Ohio State Innovation Foundation Methods and compositions related to a tissue factor-targeting IgG3 immunoconjugates
JP2020537640A (ja) * 2017-09-27 2020-12-24 オハイオ・ステイト・イノベーション・ファウンデーション 組織因子標的化ｃａｒ−ｎｋ及びｃａｒ−ｔ細胞療法
EP3833381B1 (de) * 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modifizierte faktor-vii-polypeptide zur subkutanen verabreichung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
WO1993017715A1 (en) * 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
PT771216E (pt) * 1994-07-11 2001-07-31 Scripps Research Inst Metodos e composicoes para a coagulacao especifica da vasculatura tumoral
BR9806793A (pt) * 1997-01-22 2000-05-16 Univ Texas Processos e composições de fator tissular para coagulação e tratamento de tumores.

Also Published As

Publication number Publication date
PT1198479E (pt) 2008-08-12
CA2377381A1 (en) 2001-01-11
JP2003504315A (ja) 2003-02-04
AU775621B2 (en) 2004-08-05
ES2307517T3 (es) 2008-12-01
CA2377381C (en) 2013-06-11
JP2012255032A (ja) 2012-12-27
JP5745486B2 (ja) 2015-07-08
EP1198479A4 (de) 2004-10-20
EP1198479B1 (de) 2008-06-18
DK1198479T3 (da) 2008-10-13
WO2001002439A1 (en) 2001-01-11
CY1110394T1 (el) 2015-04-29
AU5614900A (en) 2001-01-22
DE60039240D1 (de) 2008-07-31
EP1198479A1 (de) 2002-04-24

Similar Documents

Publication Publication Date Title
CY1110394T1 (el) Ανοσοσυζευγματα νεοαγγειακης στοχευσης
ES2224099T3 (es) Inmunotoxinas dirigidas contra antigenos de superficies relacionados con c-erbb-2 (her-2/neu).
Govindan et al. Designing immunoconjugates for cancer therapy
Litvak-Greenfeld et al. Risks and untoward toxicities of antibody-based immunoconjugates
DE69934337D1 (de) Konjugate zur Behandlung von Entzündungskrankheiten und von assozierter Gewebeschädigung
SA112330402B1 (ar) اتحادات جسم مضاد- عقار
ATE383430T1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
WO2004032828A3 (en) Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
HK1155070A1 (en) Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders -cd70 -
WO2013163229A1 (en) Dr5 ligand drug conjugates
JPH06509563A (ja) 炎症性関節炎の治療用の表皮細胞成長因子受容体を標的とする分子
DE69530109D1 (de) Zusammensetzung für behandlung von maligner tumore und ihre metastase
Muñoz et al. In vitro and in vivo effects of an anti-mouse endoglin (CD105)–immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours
JP2024075771A (ja) 固形腫瘍を治療するためのチューブリン破壊剤を含む抗体薬物コンジュゲートの使用
CA2366713A1 (en) Antibody and chemokine constructs and their use in the treatment of autoimmune diseases
US5690935A (en) Biotherapy of cancer by targeting TP-3/P80
CN116669772A (zh) Gpc3结合剂、其缀合物以及使用它们的方法
Rathore et al. Generation of active immunotoxins containing recombinant restrictocin
WO2004007557A3 (en) Tf antagonist
WO1990011779A1 (en) Heteroconjugates
Maiti et al. Tolerogenic conjugates of xenogeneic monoclonal antibodies with monomethoxypolyethylene glycol. I. Induction of long‐lasting tolerance to xenogeneic monoclonal antibodies
WO2022268050A1 (zh) 一种药物组合及其用途
Morgan Jr et al. Preclinical and clinical evaluation of a monoclonal antibody to a human melanoma-associated antigen
Engert et al. Experimental therapy in Hodgkin's disease
Hertler et al. Immunotoxins in the therapy of leukemias and lymphomas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1198479

Country of ref document: EP